Core B_Silvestri

核心B_Silvestri

• 批准号: 10339441
• 负责人: Guido Silvestri
• 金额: $ 106.08万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-04 至 2026-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10339441
• 关键词: Acquired Immunodeficiency Syndrome; Adherence; Adult; Animal Model; Animals; Antigens; Appearance; Autopsy; B-Lymphocytes; Behavior; Blood; Bone Marrow; Breeding; CD4 Positive T Lymphocytes; Caring; Cell Count; Cells; Chemistry; Clinical; Collection; Complete Blood Count; Complex; Control Animal; Data; Data Analyses; Data Collection; Desire for food; Dose; Eating; Ensure; Evaluation; Feces; Fine needle aspiration biopsy; Funding; Genetic; Goals; HIV; HIV Infections; HIV vaccine; Health; Health Status; Histocompatibility Antigens Class I; Housing; Human Resources; Immune response; Immunization; Immunologic Monitoring; Immunologic Surveillance; Immunologics; Immunology; Infection; Infrastructure; Intervention; Longitudinal Studies; Macaca mulatta; Microbiology; Mission; Modeling; Monitor; Movement; Physical Examination; Plasma; Play; Positioning Attribute; Prevention approach; Prevention strategy; Primates; Procedures; Protocols documentation; Quality Control; Reagent; Research; Research Design; Research Project Grants; Research Proposals; Role; SIV; Sampling; Serology; Ships; Simian T-lymphotropic virus 1; Structure of germinal center of lymph node; Substance administration; Techniques; Technology; Testing; Time; Tissues; Tuberculin Test; United States National Institutes of Health; Universities; Vaccine Clinical Trial; Vaccines; Veterinarians; Viral; Viral Load result; Viral Pathogenesis; Virus Diseases; Work; alertness; animal care; animal resource; base; clinically relevant; efficacy testing; experience; experimental study; immunogenicity; in vivo; innovation; lymph nodes; member; neutralizing antibody; nonhuman primate; novel; pre-clinical; preclinical trial; programs; protective allele; response; sample collection; simian human immunodeficiency virus; success; vaccine candidate; vaccine response; vaccine strategy; vaccine trial

Nonhuman primates (NHP) specifically, rhesus macaques (RMs), are a key animal model in investigating prevention strategies of HIV infection. This animal model of simian immunodeficiency virus (SIV)/ simian-human immunodeficiency virus (SHIV) infection has been utilized to elucidate both basic concepts in immunization and evaluate clinically relevant prevention approaches. RMs are ideal for investigating the humoral and cellular responses generated by HIV candidate immunizations and the impact on acquisition of infection. NHP studies require extensive coordination, expertise, personnel, and infrastructure. Therefore, the NHP Core (Core B) will support this HIVRAD research team by executing the four preclinical RM immunization studies proposed in Project 1. The animals will receive a variety of novel candidate immunogens and vaccine strategies. Their immune responses will be monitored throughout the study via collection of blood and tissues. Dependent upon those results, potentially, a select few animals will undergo viral challenge with SHIV to test the efficacy of the immunizations. Core B will support the success of this research program by 1) ensuring the adherence to regulatory approvals and procedures necessary for NHP research; 2) coordination of animal selection, assignment, substance administration and sample collection; 3) proper storage and shipment of all samples to the collaborating PIs and Cores; 4) coordination of data collection, analysis, and distribution; 5) and ensuring the monitoring of animal health over the course of the studies. This NHP core will work closely with the collaborators for the vaccine and challenge studies and will participate actively in the scientific mission of this HIVRAD. Further, it will ensure that all NHP research is integrated with the goals of this proposal and the evolving needs of the studies. Core B is led by Dr. Guido Silvestri, who has >20 years of experience leading NHP research projects involving complex study design and intervention, specifically, he has executed a large number of collaborative pre-clinical vaccine trials. During this research he was essential in investigating and developing novel sample collection techniques, such as lymph node fine needle aspirates, for the continued monitoring of germinal center responses during longitudinal studies. Core B will be based at Yerkes National Primate Research Center (YNPRC) at Emory University, this NIH-funded primate research center possesses all the proper animal resources and state-of-the-art veterinarian care expertise necessary to support the proposed work. As an integral part of this research program, the NHP Core will provide critical support to achieve the shared objectives of evaluating these proposed promising novel pre-clinical vaccines.

非人类灵长类动物 (NHP)，特别是恒河猴 (RM)，是研究的关键动物模型 HIV 感染的预防策略。猿猴免疫缺陷病毒（SIV）/猿-人动物模型 免疫缺陷病毒（SHIV）感染已被用来阐明免疫和预防的基本概念。 评估临床相关的预防方法。 RM 是研究体液和细胞的理想选择 HIV 候选免疫接种产生的反应以及对获得感染的影响。国民健康计划研究 需要广泛的协调、专业知识、人员和基础设施。因此，NHP 核心（核心 B）将 通过执行 4 项临床前 RM 免疫研究来支持 HIVRAD 研究团队 项目 1. 动物将接受各种新型候选免疫原和疫苗策略。他们的 在整个研究过程中，将通过收集血液和组织来监测免疫反应。依赖于 根据这些结果，可能会选择少数动物接受 SHIV 病毒攻击，以测试该药物的功效 免疫接种。核心 B 将通过以下方式支持该研究计划的成功：1) 确保遵守 NHP 研究所需的监管批准和程序； 2）动物选择的协调， 分配、物质管理和样品收集； 3) 妥善储存和运输所有样品 协作 PI 和核心； 4）协调数据收集、分析和分发； 5）并确保 在研究过程中监测动物健康。该 NHP 核心将与合作者密切合作 致力于疫苗和挑战研究，并将积极参与该 HIVRAD 的科学任务。更远， 它将确保所有 NHP 研究与本提案的目标以及不断变化的需求相结合 研究。核心 B 由 Guido Silvestri 博士领导，他拥有超过 20 年领导 NHP 研究项目的经验 涉及复杂的研究设计和干预，具体来说，他执行了大量的协作 临床前疫苗试验。在这项研究期间，他在调查和开发新样本方面发挥了重要作用 收集技术，例如淋巴结细针抽吸，用于持续监测生发中心 纵向研究期间的反应。核心 B 将设在耶基斯国家灵长类动物研究中心 (YNPRC) 位于埃默里大学，这个由 NIH 资助的灵长类动物研究中心拥有所有适当的动物 支持拟议工作所需的资源和最先进的兽医护理专业知识。作为一个整体 作为该研究计划的一部分，NHP 核心将为实现以下共同目标提供关键支持： 评估这些拟议的有前途的新型临床前疫苗。